Manufacturer Direct Programs During GLP-1 Shortage
From a clinical perspective, medication availability issues poses significant patient care difficulties that are more serious than logistical annoyance. This article covers what patients and providers should know.
Medical Consequences
Forced medication discontinuation have measurable medical impacts:
Metabolic Effects
Should someone abruptly stop their weight loss drug:
- Weight rebound: Data indicates approximately two-thirds of weight loss comes back within a year of discontinuation
- Glycemic control loss: For T2DM patients, blood sugar management deteriorates in as little as 2–4 weeks
- Hunger rebound: The hunger-reducing effects ceases within days of discontinuation
- Psychological impact: Depression, loss of control, and relationship with food disruption can emerge
Clinical Management Strategies
Titration Changes
When full doses is out of stock:
- Dose reduction: Prescribing a lower available dose preserves clinical activity and avoids abrupt cessation
- Longer injection gaps: Giving the medication less frequently instead of every 7 days — not ideal but preferable to stopping
- Dividing available supply: If the delivery device permits, splitting a higher dose into smaller administrations
Drug Switching
If one GLP-1 can’t be found anywhere:
- Switching between drug classes: Involves careful dose conversion — these aren’t interchangeable
- Injectable ↔ oral: Pen to tablet is an option but oral bioavailability is only ~1%
- Alternative drug classes: Other pharmacotherapy as a bridge until GLP-1s return
Talking to Patients
Healthcare professionals should:
- Don’t sugarcoat about shortage duration — patients deserve realistic expectations
- Keep detailed records — any changes due to supply must be in the chart
- Give patients a plan for what to do if supply can’t fill
- Monitor more closely during shortage-related changes — people with interrupted therapy should be watched carefully
Looking Ahead
Medication availability crises aren’t new — but the GLP-1 shortage stands apart in its magnitude.
Systemic solutions need:
- Additional factories — already underway but still ramping up
- Smarter supply chains — ensuring equitable access
- Regulatory responsiveness — including compounding rules that keep pace with market realities
Until then, clinicians and users have to manage these difficult conditions collaboratively.